EA033153B1 - Фармацевтическая композиция для лечения воспалительных изменений прямой кишки - Google Patents

Фармацевтическая композиция для лечения воспалительных изменений прямой кишки

Info

Publication number
EA033153B1
EA033153B1 EA201792685A EA201792685A EA033153B1 EA 033153 B1 EA033153 B1 EA 033153B1 EA 201792685 A EA201792685 A EA 201792685A EA 201792685 A EA201792685 A EA 201792685A EA 033153 B1 EA033153 B1 EA 033153B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical formulation
rectum
treatment
inflammatory changes
formulation
Prior art date
Application number
EA201792685A
Other languages
English (en)
Other versions
EA201792685A1 (ru
Inventor
Рудольф Вильхельм
Маркус Прёльс
Роланд Грайнвальд
Ральф Морбахер
Original Assignee
Др. Фальк Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Др. Фальк Фарма Гмбх filed Critical Др. Фальк Фарма Гмбх
Publication of EA201792685A1 publication Critical patent/EA201792685A1/ru
Publication of EA033153B1 publication Critical patent/EA033153B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В изобретении описывается стабильная при хранении фармацевтическая композиция для ректального применения, которая содержит будесонид, или его фармацевтически совместимую соль, или его фармацевтически совместимое производное и твердый жир или смесь разных твердых жиров в количестве по меньшей мере 80 мас.% в пересчете на общую массу композиции, а также по меньшей мере один совместимый с ними антиокислитель.
EA201792685A 2015-07-08 2016-06-28 Фармацевтическая композиция для лечения воспалительных изменений прямой кишки EA033153B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15175806.7A EP3115037B1 (de) 2015-07-08 2015-07-08 Pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des enddarms
PCT/EP2016/064907 WO2017005524A1 (de) 2015-07-08 2016-06-28 Pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des enddarms

Publications (2)

Publication Number Publication Date
EA201792685A1 EA201792685A1 (ru) 2018-07-31
EA033153B1 true EA033153B1 (ru) 2019-09-30

Family

ID=53540667

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792685A EA033153B1 (ru) 2015-07-08 2016-06-28 Фармацевтическая композиция для лечения воспалительных изменений прямой кишки

Country Status (23)

Country Link
US (3) US10905699B2 (ru)
EP (2) EP3115037B1 (ru)
JP (1) JP6857644B2 (ru)
CN (1) CN107847435B (ru)
AU (1) AU2016290343B2 (ru)
CA (1) CA2986081C (ru)
DK (1) DK3319586T3 (ru)
EA (1) EA033153B1 (ru)
ES (2) ES2688119T3 (ru)
FI (1) FI3319586T3 (ru)
HR (1) HRP20230174T1 (ru)
HU (1) HUE061585T2 (ru)
IL (1) IL255247B (ru)
LT (1) LT3319586T (ru)
MA (1) MA42367B1 (ru)
MD (1) MD3319586T2 (ru)
PL (1) PL3319586T3 (ru)
PT (2) PT3115037T (ru)
RS (1) RS64020B1 (ru)
SI (1) SI3319586T1 (ru)
UA (1) UA120075C2 (ru)
WO (1) WO2017005524A1 (ru)
ZA (1) ZA201707777B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022226778A1 (zh) * 2021-04-27 2022-11-03 广州共禾医药科技有限公司 经直肠施用的奥司他韦或其药学上可接受的盐的药物组合物、及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
DE19849737A1 (de) * 1998-10-28 2000-05-04 Falk Pharma Gmbh Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen
WO2008156671A2 (en) * 2007-06-13 2008-12-24 Jay Pravda Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB701831A (en) * 1950-10-19 1954-01-06 Rudolf Von Wuelfing Process for the production of suppositories containing medicaments
US3208907A (en) * 1961-11-13 1965-09-28 Lab Toraude Stabilized salicylate compositions
DE3709861A1 (de) * 1987-03-25 1988-10-06 Henkel Kgaa Emulgierende suppositoriengrundmassen und daraus hergestellte zaepfchen
JP2927830B2 (ja) * 1989-09-01 1999-07-28 東京田辺製薬株式会社 ダナゾール坐剤
IT1243379B (it) 1990-07-27 1994-06-10 Giuliani Spa Composizione farmaceutica adatta alla somministrazione rettale di principi attivi che esplicano un'azione di medicazione a livello del colon prevalentemente di tipo topico
US20020085978A1 (en) * 2000-11-10 2002-07-04 Mina Buenafe Degradation-resistant glucocorticosteroid formulations
CU23203A1 (es) * 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Formulaciones que contienen agentes de accion trombolitica para su administracion por via rectal
JP5223307B2 (ja) * 2006-11-17 2013-06-26 大正製薬株式会社 坐剤
EP2364161B1 (en) * 2008-11-26 2020-03-11 Satiogen Pharmaceuticals, Inc. Compositions containing satiogens and methods of use
WO2012022796A2 (de) * 2010-08-20 2012-02-23 Boehringer Ingelheim International Gmbh Neue kombinationen
CN102525883B (zh) * 2010-12-09 2013-05-08 丽珠集团丽珠制药厂 一种伏立康唑栓剂及其制备方法和用途
WO2015073846A1 (en) 2013-11-15 2015-05-21 Salix Pharmaceuticals, Inc. Method of treating ulcerative colitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
DE19849737A1 (de) * 1998-10-28 2000-05-04 Falk Pharma Gmbh Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen
WO2008156671A2 (en) * 2007-06-13 2008-12-24 Jay Pravda Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Also Published As

Publication number Publication date
CA2986081A1 (en) 2017-01-12
FI3319586T3 (fi) 2023-03-22
PL3319586T3 (pl) 2023-05-08
IL255247A0 (en) 2017-12-31
EP3319586B1 (de) 2023-01-18
HUE061585T2 (hu) 2023-07-28
CN107847435A (zh) 2018-03-27
EA201792685A1 (ru) 2018-07-31
CN107847435B (zh) 2021-07-27
MA42367B1 (fr) 2023-02-28
US20230364113A1 (en) 2023-11-16
MD3319586T2 (ro) 2023-04-30
NZ736749A (en) 2023-12-22
US20180200268A1 (en) 2018-07-19
SI3319586T1 (sl) 2023-03-31
UA120075C2 (uk) 2019-09-25
US11738032B2 (en) 2023-08-29
PT3319586T (pt) 2023-02-14
EP3115037A1 (de) 2017-01-11
AU2016290343B2 (en) 2020-10-15
CA2986081C (en) 2024-02-20
RS64020B1 (sr) 2023-03-31
EP3115037B1 (de) 2018-08-15
ZA201707777B (en) 2018-11-28
ES2688119T3 (es) 2018-10-31
DK3319586T3 (da) 2023-02-27
ES2938358T3 (es) 2023-04-10
MA42367A (fr) 2018-05-16
WO2017005524A1 (de) 2017-01-12
HRP20230174T1 (hr) 2023-04-14
AU2016290343A1 (en) 2017-11-16
LT3319586T (lt) 2023-03-10
JP2018519345A (ja) 2018-07-19
EP3319586A1 (de) 2018-05-16
US20210100819A1 (en) 2021-04-08
PT3115037T (pt) 2018-10-22
US10905699B2 (en) 2021-02-02
JP6857644B2 (ja) 2021-04-14
IL255247B (en) 2020-11-30

Similar Documents

Publication Publication Date Title
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX2016014509A (es) Formulacion de vitamina soluble en grasa.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
NZ738197A (en) Antihypertensive agent
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
PH12019501999A1 (en) Pyrazole derivatives as bromodomain inhibitors
MX2016004909A (es) Composicion que contiene eugenol como principio activo para prevenir o tratar la dermatitis atopica.
EA033153B1 (ru) Фармацевтическая композиция для лечения воспалительных изменений прямой кишки
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
PH12019500024A1 (en) Pharmaceutical compositions
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif